| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Clinique des Maladies Respiratoires Hôpital Arnaud de Villeneuve, CHU de Montpellier, France and 2 AstraZeneca R&D, Lund, Sweden
CORRESPONDENCE: P. Chanez, Hôpital Arnaud de Villeneuve, CHU de Montpellier, 34295-Montpellier-Cedex 5, France. Fax: 33 467521848
Keywords: airway pharmacology, budesonide, mild-to-moderate asthma, treatment strategy
Received: January 15, 2000
Accepted January 15, 2001
Guidelines on the use of inhaled steroids in asthma advocate that the daily dose should be chosen according to the severity of the disease. However, the question of the optimal starting dose remains to be properly addressed, as does the issue of the adjustment in dose required for a given patient.
Whether a high initial dose of budesonide (800 µg b.i.d) was more efficacious than a standard dose (200 µg b.i.d) in controlling mild-to-moderate asthma was investigated, and whether the dose could be decreased, based on peak expiratory flow (PEF), symptom-score, ß2-agonist use in a double-blind, randomized, parallel-group 18-week study.
One-hundred and sixty-nine patients (mean age 38 yrs, mean forced expiratory volume in one second 74% predicted) were enrolled. No difference was detected between the two groups in improvement in morning PEF (+61 L·min–1 in the high-dose group, +60 L·min–1 in the standard-dose group by 16 weeks). Morning and evening PEF values stabilized before the end of the first 4 weeks.
No difference between groups was observed in symptom score, ß2-agonist use, number of exacerbation per interval and the best forced expiratory volume in one second achieved. The proportion of subjects being able to decrease the doses of budesonide was similar in both treatment strategies. It is concluded that both high and standard initial doses are equally effective in controlling symptoms and improving lung function in mild-to-moderate asthma.
This article has been cited by other articles:
|
|
 |
|
  E. Zervas, E. Oikonomidou, E. Kainis, M. Kokkala, K. Petroheilou, and M. Gaga Review: Control of asthma Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 141 - 148. [Abstract] [PDF]
|
|
|
|
 |
|
 H Powell and P G Gibson Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review Thorax, December 1, 2004; 59(12): 1041 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Masoli, S. Holt, M. Weatherall, and R. Beasley Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis Eur. Respir. J., April 1, 2004; 23(4): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Baumgartner, G. Martinez, J.M. Edelman, G.G. Rodriguez Gomez, M. Bernstein, S. Bird, R. Angner, A. Polis, S.B. Dass, S. Lu, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone Eur. Respir. J., January 1, 2003; 21(1): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. VISSER, D. S. POSTMA, L. R. ARENDS, T. W. DE VRIES, E. J. DUIVERMAN, and P. L. P. BRAND One-Year Treatment with Different Dosing Schedules of Fluticasone Propionate in Childhood Asthma . Effects on Hyperresponsiveness, Lung Function, and Height Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2073 - 2077. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
